Drug Trial Radar · NCT06712082
A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Feb 24, 2025
Primary completion
Sep 4, 2025
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn if the study medicine (called PF-07264660) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who: * are between 18 to 65 years of age. * are Chinese participants who are overtly healthy as determined by medical evaluation. * have a BMI (body mass index) of 19 to 28 kilogram per meter squared; and a total body weight of more than50 kilograms (110 pounds). All participants in this study will receive study medicine. Three-fourths will receive PF-07264660 and one-fourth will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The study medicine will be given as an IV infusion (directly into a vein) at the study clinic only one time. The study will compare the experiences of people receiving PF-07264660 to those of people who do not. This will help see if PF-07264660 is safe and how it behaves inside the human body. Participants will take part in this study for up to 181 days. During this time, the participants will stay at the study clinic for 5 days. After the stay, the participants will have 8 study visits at the study clinic.
Conditions
- Healthy
Interventions
PF-07264660Drug
PF-07264660 solution for injection (single use only)
PlaceboOther
Placebo solution for injection (single use only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 181
- Time to Reach Maximum Observed Plasma Concentration (Tmax)Time frame: Up to Day181
- area under the concentration-time curve from time 0 to 336 hours (AUC336)Time frame: Up to Day 181
- area under the concentration-time curve from time 0 to infinity (AUCinf)Time frame: Up to Day 181
- area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)Time frame: Up to Day 181
- Terminal phase half-life (t½)Time frame: Up to Day 181
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: Up to Day 181
- Incidence of treatment-emergent serious adverse events (SAEs)Time frame: Up to Day 181
- Incidence of abnormal and clinically relevant changes in vital signsTime frame: Up to Day 181
- Incidence of abnormal and clinically relevant changes in electrocardiogramTime frame: Up to Day 181
- Incidence of abnormal and clinically relevant changes in laboratory assessmentsTime frame: Up to Day 181
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Huashan Hospital,Fudan University
Shanghai, Shanghai Municipality, China
Huashan Hospital,Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.